Jenex to Test Next Generation Technology, TherOZap(TM) Against the Zika Virus and West Nile Virus

About this update from Therma Bright Inc.

Jenex to Test Next Generation Technology, TherOZap(TM) Against the Zika Virus and West Nile VirusTORONTO, ON / ACCESSWIRE / December 8, 2016 / The Jenex Corporation (TSX-V: JEN.H) ("Jenex", or the "Company") plans to test next generation technology, TherOZap™, against the Zika Virus and the West Nile Virus. Rob Fia, CEO and Chairman of Jenex, reports that the Company will undergo testing of its patent pending technology, TherOZap™, against the Zika and West Nile virus. Jenex has engaged an independent lab and an internationally recognized health care network to conduct the tests. The tests will determine if the Zika and West Nile viruses are susceptible to the treatment conditions of the technology, including the identification of effective treatment parameter ranges. "We are pleased to test our patent pending TherOZap™ technology against both the Zika and West Nile virus, especially given the wide spread of the Zika virus around the world," says Fia. "We are excited about these initial steps, but caution that it is too early to say if the technology will have any effect at this stage against the Zika or West Nile virus. Jenex has engaged a world renowned lab that is preparing to initiate testing of our technology to determine if it can be effective in inactivating the virus. We look forward to providing an update on the initial results of the tests in the near future." Chris Cook, CEO and Chairman of Luminar Media Group, Inc., (Luminar), and global licensee for TherOZap™ outside of Canada, comments: "The possibility that this research may provide an opportunity to mitigate the global risk associated with mosquito borne diseases, such as Zika, is exciting. We are hopeful that our licensed TherOZap™ technology will have a positive effect at reducing the harm associated with the Zika virus." Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, including bees, wasps, hornets, mosquitoes, black flies, and jellyfish. Jenex received approval for the above claims from the FDA (United States) in 1997. Jenex continues to further develop and explore other applications for its platform technology. If you would like to stay informed on the development of TherOZap™ please ...

View stock analysis, news, and events for Therma Bright Inc.